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Abstract
BACKGROUND: Acute esophageal damage may be a dose-limited factor for application the full planning radiotherapy 
(RT) dose in patients with inoperable non-small cell lung cancer (NSCLC). A combination of chemotherapy and RT 
may increase esophageal toxicity, but three-dimensional (3D) conformal RT offers better sparing of the organs at risk.
AIM: The purpose of this study was to show the incidence and degree of acute esophageal damage in lung cancer 
patients treated with sequential and concurrent chemoradiotherapy.
MATERIALS AND METHODS: The total number was 73 patients, of whom 26 (34.7%) had previously received 
sequential chemotherapy with a four-cycle followed by RT. In the second concurrent group, 47 (65.3%) patients were 
received concomitant chemotherapy and RT.
RESULTS: Of the 73 patients included in the study, 43 (57.3%) did not present any grade of esophagitis during the 
treatment. In the sequential group, 73.1% presented no esophagitis and in the concurrent group, 49%, respectively. 
Although there were differences between the two groups, none were statistically significant.
CONCLUSIONS: The reason for the good tolerability of the combination of chemotherapy and RT for inoperable 
NSCLC patients was using 3D conformal RT. Further improvements may be obtained with more sophisticated RT or 
radioprotective drugs.
Introduction
Lung cancer remains a worldwide epidemic. 
Approximately 1.2 million people die from lung cancer 
each year. Non-small cell lung cancer (NSCLC) 
represents >80% of all lung cancers. Of the patients 
with NSCLC, 60–70% present with Stage III or IV 
disease [1]. In the late 1980s, radiotherapy (RT) was the 
standard treatment for inoperable lung cancer patients. 
Randomized trials and a 1995 overview subsequently 
showed that combination chemoradiotherapy was 
superior to RT alone. Many chemotherapeutic agents 
active in NSCLC possess radiosensitizing properties, 
thereby improving the probability of local control. In 
addition, chemotherapy administered concurrent with 
thoracic radiation may act systemically and potentially 
eradicate distant micrometastases. Several studies 
showed the feasibility of the cisplatin-etoposide 
combination plus RT for patients with Stage III 
disease [2], [3]. Acute esophagitis occurring ≤90 days 
after treatment is a common side effect of patients 
undergoing RT for thoracic tumors. Concurrent 
chemoradiotherapy results in a 15–25% rate of 
severe (RT oncology group RTOG) Grade 3 or greater 
acute esophagitis [4] that can require hospitalization, 
invasive diagnostic tests (endoscopy) surgical 
intervention (percutaneous endoscopic gastrostomy 
tube) or RT breaks that could lower local tumor 
control [5], [6], [7], [8], [9]. Acute esophagitis occurs 
during RT and often persists for several weeks after 
RT. The symptoms of severe esophagitis (Grade 3 or 
greater) typically peak 4–8 weeks from the beginning 
of RT. Late esophageal damage, typically stricture 
and associated dysphagia, develops 3–8 months after 
RT [10]. Abnormal esophageal motility can be noted 
within 3–4 weeks from RT alone and as early as 1 week 
after starting concurrent chemoradiotherapy [11]. The 
adult esophagus length is approximately 25 cm and 
is defined by its external contour on axial computed 
tomography (CT) images. It is recommended that 
the entire length of the esophagus, from the cricoid 
cartilage to the gastroesophageal junction, be 
identified, requiring that portion of the neck and upper 
abdomen be included in the planning CT scan. In 
some of the studies [10], [11], the cervical esophagus 
was not included, casing the absolute esophageal 
volume to be 20% smaller than if its entirety had been 
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contoured. The degree of damage of the esophagus is 
proportional with the volume involved in the radiation 
fields and with daily radiation dose and total radiation 
dose. In the literature, there are small numbers of 
the studies analyzed esophageal damage in patients 
with inoperable NSCLC treated with concurrent and 
sequential chemoradiotherapy. The purpose of this 
study is to show the incidence and degree of acute 
esophageal damage in lung cancer patients treated 
with sequential and concurrent chemoradiotherapy.
Materials and Methods
This study was started at the Clinic of RT 
and Oncology in Skopje, March 2010. To evaluate the 
treatment results, a study of 73 patients was randomly 
assigned to one of the two treatment arms. In the 
sequential arm, 26 (34.7%) patients had previously 
received sequential chemotherapy with four cycles of 
carboplatin and etoposide followed by conformal RT. In 
the second concurrent arm, 49 (65.3%) patients received 
concurrent chemotherapy of cisplatin and etoposide 
and conformal RT. Eligible 73 patients were aged 
between 18 and 70 years, had an Eastern Cooperative 
Oncology Group Score ≤1, and had ≤10% weight loss 
in the period of 3 months before inclusion. They have 
previously untreated histological or cytological proven 
NSCLC, unrespectable Stage IIIA-N2 disease, or Stage 
IIIB disease without pleural effusion. Stage IIIB disease 
was assigned either by N3 (contralateral mediastinal 
or supraclavicular nodes) or by T4 from invasion of 
mediastinal structures. The following laboratory values 
were required: Leukocytes ≥1.5 × 10³/l, platelets ≥100 × 
10/l, and AST and ALT ≤2 × the upper limit of the referent 
rang. Ineligibility criteria were as follows: Uncontrolled 
infection, or fever over 38°C, unstable cardiovascular 
disease, and previous malignancy.
Patients were randomly assigned to receive 
sequential or concurrent therapy. In the sequential 
arm, 26 patients received four cycles of chemotherapy. 
They were administered first, consisting of carboplatin 
(AUC × 6) on day 1 and etoposide on days 1–3, repeated 
every 3 weeks. The RT began 4 weeks after the fourth 
cycle of chemotherapy administration. Chemotherapy and 
RT began simultaneously in concurrent arm consisted of 
47 patients. The RT schedule was identical to that in the 
sequential arm. The first cycle with cisplatin 30 mg/m² and 
etoposide 100 mg/m² was administered on days 1–3 and 
the second 3-days cycle was administered the last 3 days 
of RT. After 4 weeks of concurrent chemoradiotherapy 
schedule, two cycles of consolidation chemotherapy 
began, consisting of carboplatin (AUC × 6) and etoposide 
100 mg/m² on day 1–3.
Conformal RT at both arms consisted of 60 Gy in 
30 fractions of 2 Gy per fraction, for 5 days a week given 
over a period of 6 weeks. A treatment planning CT was 
required to define the gross tumor volume (GTV). Each 
patient was positioned in an immobilization device-wing 
board in the treatment position on a flat table. CT slices 
with 5 mm thickness were obtained starting from cricoid 
cartilage and extending inferiorly to the level of the L1 
vertebral body. The GTV, clinical target volume (CTV), 
planning target volume (PTV), and normal organs were 
outlined on all CT slices. The normal tissues contoured 
included lungs (as the total lung volume), heart, spinal 
cord, and esophagus. The CTV included the entire 
GTV plus 0.5 cm and the PTV included CTV plus 
another 0.5 cm adding margin. PTV44 was treated with 
parallel-opposed anterior-posterior fields and PTV60 
was treated with any combination of fields depends 
of spinal cord constrain. Contouring of target volumes 
and normal organs esophagus, spinal cord, heart, and 
lung was performed on each slide. The external surface 
of the esophagus was delineated on each axial plane 
of the planning CT scan from the level of the lower 
end of the cricoid cartilage to the gastroesophageal 
junction. Patients had their entire esophagus, including 
esophageal internal lumen contoured. Maximum 
acceptable doses for dose-limiting organs were lung 
V20 <37%, and esophageal maximum dose V45 of 
<40%, V55 of <28%. Dose distribution and dose-
volume histograms for the esophagus were calculated 
according to the Varian system.
During the course of RT, patients were 
observed at least weekly and more often if the need 
for clinical evaluation and treatment of complaints. 
Acute esophageal toxicity was determined during the 
weekly visit and at clinical follow-ups after 1 month 
and 2 months, respectively. Acute esophageal toxicity 
<3 months was graded by the RTOG criteria. These 
criteria are grading acute esophageal damage as 
Grade 1 due to mild dysphagia or odynophagia, 
requiring topical anesthetic, non-narcotic agents, or 
soft diet, Grade 2 moderate dysphagia or odynophagia 
requiring narcotic agents or liquid diet, Grade 3 severe 
dysphagia or odynophagia with deshydratation or 
weight loss >15% of pre-treatment baseline requiring 
nasogastric feeding, and Grade 4 complete obstruction, 
ulceration, perforation, or fistula. If RT had to be delayed 
for more than 7 days, the patient was withdrawn from 
the study. Patients with evidence of progression at any 
time were removed from the study but continued to 
be evaluated for survival and toxicity. Survival and the 
interval to recurrence or progression were measured 
from the date of the first treatment session.
Results
From 2010 to 2013, at the University Clinic of 
RT and Oncology in Skopje, 73 patients were enrolled. 
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The median OS was 13 months for the patients in 
the sequential arm and 19 months for those in the 
concurrent treatment arm (p = 0.0039) Figure 1.
have shown that, compared to RT alone, the addition 
of concurrent or sequential chemoradiotherapy to 
radiation appears to lower esophageal tolerance [12]. 
A meta-analysis of 19 randomized trials of a radical 
cathode-ray tube (CRT) versus RT alone, including 
concurrent and sequential systemic therapy, reported 
that the addition of chemotherapy increases acute 
esophagitis by approximately 5 times [13]. In a study 
by Byhardit et al., in patients with locally advanced 
NSCLC, the incidence of severe acute esophagitis with 
standard RT alone 60–69 Gy/30 was 1.3%; concurrent 
chemotherapy increased this to 14–49% 24–5. Radical 
RT alone results in significantly lower rates of Grade 3 
or higher esophagitis (1–2%) [14].
Older techniques using two-dimensional (2D) 
planning are more likely to cause side effects than 
modern technologies [15]. In comparison with the 
2D RT, three-dimensional (3D) conformal RT results 
in Grade 2 esophagitis in 32%, Grade 3 in 10–17%, 
and Grade 4 in 0.9% [16], [17]. The incidence of 
severe acute esophagitis in our study was lower than 
for other studies of patients with lung cancer treated 
with 3D-CRT [18], [19]. It is well known that acute 
esophagitis affects the quality of the life of lung cancer 
patients, and may precipitate a break in radiation 
treatment. In this study, RT treatment interruptions due 
to severe esophagitis were not observed. The median 
dose administered in our study was 60 Gy which was 
slightly lower the prescribed dose of 66 Gy in other 
conformal RT. Acute radiation injuries usually occur in 
the 3rd–4th week of RT and tend to increase severity 
toward the end of treatment [20]. These findings also 
showed that the appearance of Grade 3 or higher acute 
esophagitis was similar to other published studies [21]. 
None of patient experienced Grade 4 esophagitis. 
Although dose-volume parameters are commonly 
used to analyze the risk of acute esophagitis, there 
is a significant degree of dissimilarity among the 
other published studies regarding which dose-volume 
parameters have the most dominant effect on the risk of 
acute esophagitis [22]. Some reports show esophageal 
volume 40 Gy associated with acute esophagitis [18], 
others mentioned no association between the risk of 
acute esophagitis and volumes of the esophagus [8]. 
At present, it is not possible to identify a single best 
threshold parameters associate significantly with mild 
Figure 1: Overall survival according to treatment, concurrent versus 
sequential chemoradiotherapy
For 73 patients included in the study, 43 (57.3%) 
did not present any grade of esophagitis during the 
treatment. In the sequential group, 73.1% presented 
no esophagitis and in the concurrent group, 49%, 
respectively. Although there were differences between 
the two groups, it was not statistically significant. There 
was not any Grade 4 esophageal damage in both 
groups. Tables 1 and 2 summarize the esophageal 
damage in both treatment groups according to radiation 
doses. The risk of esophagitis was 22%, in patients 
whose esophageal volume (V50) received <30% of 
prescribed dose in comparison, the risk of esophagitis 
was 71%, in patients whose V50 received dose higher 
than 30% (p = 0.0009).
Discussion
This study was a prospective report of treatment-
related acute toxicities of the esophagus in a patient 
with lung cancer that was administered concurrent 
and sequential RT and chemotherapy. Several studies 
Table 1: Grade of esophagitis according to RT doses
Radiation dose Sequential arm (%) Concurrent arm (%)
0 1 2 3 0 1 2 3
40 Gy 22 (84.6) 1 (3.8) 3 (11.5) 0 30 (61.2) 8 (16.3) 9 (18.4) 2 (4.1)
60 Gy 20 (76.9) 0 6 (23.1) 0 25 (51.0) 7 (14.3) 15 (30.6) 3 (6.1)
End of RT 19 (73.1) 1 (3.8) 6 (23.1) 0 28 (84.6) 4 (8.2) 14 (28.6) 3 (6.1)
0, 1, 2, 3= grade of esophagitis according RTOG/EORTG. RT: Radiotherapy.
Table 2: Irradiation doses and analgesia
Radiation dose Sequential arm (%) Concurrent arm (%)
0 1 2 3 0 1 2 3
40 Gy 22 (84.6) 1 (3.8) 0 3 (11.5) 30 (61.2) 11 (22.4) 4 (8.2) 4 (8.2)
60 Gy 21 (80.8) 1 (3.8) 1 (3.8) 3 (11.5) 25 (51.0) 12 (24.4) 4 (8.2) 8 (16.3)
End of RT 20 (76.9) 1 (3.8) 2 (7.7) 3 (11.5) 31 (63.3) 7 (14.3) 2 (4.1) 9 (18.4)
0 = no analgesia; 1 = anti-inflammatory drugs; 2 = opioids; 3 = combination of anti-inflammatory drugs and opioids. RT: Radiotherapy.
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to severe acute esophagitis. Exempting the entire 
esophageal length/volume from the high-dose 
radiation region is extremely difficult. Decreasing the 
radiation dose delivered to a part of the esophageal 
margin might be feasible with better RT techniques, 
in particular, the studies we analyzed illustrate a clear 
trend demonstrating that volumes receiving >40–50 Gy 
correlated significantly with acute esophagitis [22]. 
A study by Gomez et al. [23] showed that patients with 
NSCLC treated with intensity-modulated RT (IMRT) 
have the highest rate of Grade 3 acute esophagitis 
when compared with 3DCRT and RT. The authors 
speculate that this could be due to the “lower-dose 
bath” received by the esophagus with IMRT, whereas 
3DCRT and RT allow complete or partial sparing 
of the esophagus. The Belderbos et al. study [18] 
finds that when accepting a 30% risk of developing 
esophagitis grade ≥2, a maximum volume of 50% of 
the esophagus can be irradiated to 35% Gy. This dose/
volume recommendation for the esophagus is also 
given by QUANTEC [24]. Our results indicated that in 
the treatment of lung cancer patients, highly conformal 
RT reduces the risk of esophagitis to a minor problem. 
For better esophageal spearing and providing a better 
quality of life for our lung cancer patients in the future, 
we planning to use 18-fluoro-deoxy-glucose positron 
emission tomography CT scan in the RT treatment 
planning process.
Conclusions
The reason for the good tolerability of the 
combination of chemotherapy and RT for inoperable 
NSCLC patients in our study was using 3D conformal 
RT. Further improvements may be obtained with more 
sophisticated RT and treatment planning or further 
research in radioprotective agents.
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